CD274 and cancer: In the clinical trial KEYNOTE-158 assessing efficacy of pembrolizumab (anti- PD-L1) in non-colorectal MSI high/MMRd cancers (n = 233), objective response rates were 45.8% in gastric, 42.1% in small intestine and 40.9% in cholangiocarcinoma, and 18.2% in pancreatic cancers [15].